Cefdinir: Difference between revisions

No edit summary
Line 5: Line 5:

==Adult Dosing==
==Adult Dosing==
*600 mg/d divided q12-24hrs for 10 days for CAP, chronic bronchitis, acute sinusitis, strep pharyngitis, cellulitis
*600 mg/d divided q12-24hrs for 10 days for [[CAP]], chronic [[bronchitis]], acute [[sinusitis]], [[strep pharyngitis]], [[cellulitis]]

==Pediatric Dosing==
==Pediatric Dosing==

Revision as of 13:16, 21 January 2016


  • Type: Third generation cephalosporin
  • Dosage Forms: 300 mg oral solid, 125/5ml susp, 250/5ml susp
  • Common Trade Names: Omnicef

Adult Dosing

Pediatric Dosing

  • 14 mg/kg/d PO divided q12-24hrs x10 days, max of 600 mg/day

Special Populations

  • Pregnancy Rating: B
  • Lactation: Probably safe
  • Renal Dosing
    • Adult: CrCl <30, 300mg q24hrs; CrCl <10, 300mg q48hrs; supplement after HD
    • Pediatric: CrCl <30, 7mg/kg q24, max 300mg/dose; supplement after HD
  • Hepatic dosing not defined


  • Allergy to class/drug

Adverse Reactions




  • Half-life:
  • Metabolism:
  • Excretion:
  • Mechanism of Action:

Antibiotic Sensitivities[1]

Group Organism Sensitivity
Gram Positive Strep. Group A, B, C, G S
Strep. Pneumoniae S
Viridans strep S
Strep. anginosus gp X1
Enterococcus faecalis R
Enterococcus faecium X1
Staph. Epidermidis I
C. jeikeium X1
L. monocytogenes R
Gram Negatives N. gonorrhoeae S
N. meningitidis X1
Moraxella catarrhalis S
H. influenzae S
E. coli S
Klebsiella sp S
E. coli/Klebsiella ESBL+ R
E coli/Klebsiella KPC+ R
Enterobacter sp, AmpC neg R
Enterobacter sp, AmpC pos R
Serratia sp R
Serratia marcescens X1
Salmonella sp S
Shigella sp S
Proteus mirabilis S
Proteus vulgaris I
Providencia sp. X1
Morganella sp. R
Citrobacter freundii R
Citrobacter diversus X1
Citrobacter sp. S
Aeromonas sp X1
Acinetobacter sp. X1
Pseudomonas aeruginosa R
Burkholderia cepacia X1
Stenotrophomonas maltophilia X1
Yersinia enterocolitica X1
Francisella tularensis X1
Brucella sp. X1
Legionella sp. R
Pasteurella multocida S
Haemophilus ducreyi X1
Vibrio vulnificus X1
Misc Chlamydophila sp X1
Mycoplasm pneumoniae X1
Rickettsia sp X1
Mycobacterium avium X1
Anaerobes Actinomyces X1
Bacteroides fragilis X1
Prevotella melaninogenica X1
Clostridium difficile X1
Clostridium (not difficile) X1
Fusobacterium necrophorum X1
Peptostreptococcus sp. X1


  • S susceptible/sensitive (usually)
  • I intermediate (variably susceptible/resistant)
  • R resistant (or not effective clinically)
  • S+ synergistic with cell wall antibiotics
  • U sensitive for UTI only (non systemic infection)
  • X1 no data
  • X2 active in vitro, but not used clinically
  • X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
  • X4 active in vitro, but not clinically effective for strep pneumonia

See Also


  1. Sanford Guide to Antimicrobial Therapy 2014